Major reasons for launching this Action

The major objective of the ADMIRE COST Action is to improve knowledge-sharing, expertise, discoveries, tools and access to clinical samples within a connected research community. This will facilitate more effective translation of research knowledge into clinical practice benefiting patients worldwide. The ADMIRE COST action covers almost all aspects of aldosterone and mineralocorticoid biology, physiology, pathophysiology, clinical outcomes and therapeutic applications making it unique in a global context.

The Action will allow the consortium to:

  1. structure and enhance the excellence of European research in the field to increase its international impact;
  2. rapidly identify novel clinical indications for MR antagonists;
  3. identify new signalling pathways of aldosterone/MR to uncover new therapeutic targets;
  4. develop new biomarkers of aldosterone/MR activation in order to better identify patients aimed to receive such personalised therapy;
  5. stimulate interest of Small-Medium Enterprises (SMEs) and large pharmaceutical companies in novel targets and biomarkers to develop diagnostic tools and drugs.

 

Why this field needs a COST action

  • Improve cross-disciplinary working

    There is a need to defragment and strengthen European research in the field to re-establish an international leader position. Cross disciplinary collaborations will be facilitated by networking well-established and emerging teams in Europe with global collaborations (hands-on training workshops, summer schools, conferences, student exchanges with Short Term Scientific Missions-STSM).

  • Important economic societal and scientific benefit of the COST action

    According the World Health Organisation, hypertension – high blood pressure -is “the leading global risk for mortality in the world”. The WHO puts hypertension above even tobacco use as a preventable risk factor, and they state that “Globally, 51% of stroke and 45% of ischaemic heart disease deaths are attributable to high systolic blood pressure”. Nearly 13% of all global deaths (estimates vary) are attributable to hypertension. This means that globally hypertension is responsible for around 7.5 million premature deaths per year. Hypertension is a major cause of premature death in the European population. The World Health Organisation estimates that 36% of Europeans aged 30 or older have high blood pressure, which means that around 200 million people in greater Europe (i.e. not just the EU) will have hypertension. Moreover cardiovascular diseases (related or not to hypertension) renal diseases (with end stage chronic kidney diseases requiring replacement therapy), or metabolic diseases, can be viewed as epidemic in the next century. This explosion in cardiovascular disease among the EU population is mainly due to ageing and changes in environmental habits (food, decrease exercise practice, stress, bad social conditions for example).

    This COST Action will improve the European health status in hypertension by accelerating the transfer of knowledge from a network of scientists and clinicians to patient care, especially in novel clinical domains where efficient treatment is still lacking or poorly translated. Moreover improved diagnostic tools will help reduce treatment costs and lead to scientific and economic benefits (including reduction in health care costs and increased biotechnology intellectual property rights). The specific attention to a balanced STSM gender approach in this COST Action will help promote and retain talented early stage researchers in the European Research Area.

  • Empowering current European research

    This COST Action will accelerate the interaction among the teams of the consortium, stimulate new collaborations, extending previous ones to multi-disciplinary approaches and promote bench to bedside translation.

  • Data sharing and translation

    Emerging data within the network will be quickly accessible to the rest of the network and interested SMEs. A major outcome will be to accelerate translation to clinical studies and trials for novel therapeutic (e.g. MR antagonists) or diagnostic tools.

  • Building Europe for the future of medicine

    A fundamental aspect of this Action will be the development, education and integration of emerging early stage researchers in world-leading laboratories. Moreover training of medical doctors in basic research will further strength European clinical research. A further benefit will be the establishment of a European-wide research collaborative network among leading laboratories of different European countries. We expect this network to become self-sustaining after the completion of the COST Action. Teams from 10 European Member States, plus 2 third countries, will be involved in this COST Action and will favour researcher mobility through staff exchanges between labs, especially for Early Stage Researchers who will form the next generation of team leaders for European Research in hypertension and aldosterone.